Prezista Gets New Warning On Hepatotoxicity
This article was originally published in The Pink Sheet Daily
FDA issues Medwatch Alert advising health care professionals of updated labeling for Johnson & Johnson’s protease inhibitor.
You may also be interested in...
Darunavir - formerly known as TMC-114 - in combination with ritonavir is approved for treatment-experienced adults who do not respond to other antiretrovirals.
The company is planning a direct-to-consumer education campaign to inform the public about the importance of vaccination.
The company showcased its pipeline in a two-day virtual meeting, trying to convince investors the long-term potential is undervalued.